These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31776449)

  • 1. Serum biomarkers combined with ultrasonography for early diagnosis of non-alcoholic fatty liver disease confirmed by magnetic resonance spectroscopy.
    Qian LL; Wu L; Zhang L; Zhang J; Zhou J; Li YH; Fang QC; Li HT; Jia WP
    Acta Pharmacol Sin; 2020 Apr; 41(4):554-560. PubMed ID: 31776449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy of prediction scores and novel biomarkers for predicting nonalcoholic fatty liver disease in obese children.
    Koot BG; van der Baan-Slootweg OH; Bohte AE; Nederveen AJ; van Werven JR; Tamminga-Smeulders CL; Merkus MP; Schaap FG; Jansen PL; Stoker J; Benninga MA
    Obesity (Silver Spring); 2013 Mar; 21(3):583-90. PubMed ID: 23592667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of alcoholic liver disease (ALD)/nonalcoholic fatty liver disease (NAFLD) index combined with γ-glutamyl transferase in differentiating ALD and NAFLD.
    Wang J; Li P; Jiang Z; Yang Q; Mi Y; Liu Y; Shi R; Zhou Y; Wang J; Lu W; Li S; Liu D
    Korean J Intern Med; 2016 May; 31(3):479-87. PubMed ID: 27025268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease.
    Wu G; Li H; Fang Q; Zhang J; Zhang M; Zhang L; Wu L; Hou X; Lu J; Bao Y; Jia W
    Sci Rep; 2017 Jul; 7(1):5095. PubMed ID: 28698650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor-21 and omentin-1 hepatic mRNA expression and serum levels in morbidly obese women with non-alcoholic fatty liver disease.
    Waluga M; Kukla M; Zorniak M; Kajor M; Liszka L; Dyaczynski M; Kowalski G; Zadlo D; Waluga E; Olczyk P; Buldak RJ; Berdowska A; Hartleb M
    J Physiol Pharmacol; 2017 Jun; 68(3):363-374. PubMed ID: 28820393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology.
    Calvo N; Beltrán-Debón R; Rodríguez-Gallego E; Hernández-Aguilera A; Guirro M; Mariné-Casadó R; Millá L; Alegret JM; Sabench F; del Castillo D; Vinaixa M; Rodríguez MÀ; Correig X; García-Álvarez R; Menendez JA; Camps J; Joven J
    World J Gastroenterol; 2015 Jun; 21(24):7529-44. PubMed ID: 26140000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast Growth Factor-21 to Adiponectin Ratio: A Potential Biomarker to Monitor Liver Fat in Children With Obesity.
    Tas E; Bai S; Ou X; Mercer K; Lin H; Mansfield K; Buchmann R; Diaz EC; Oden J; Børsheim E; Adams SH; Dranoff J
    Front Endocrinol (Lausanne); 2020; 11():654. PubMed ID: 33071964
    [No Abstract]   [Full Text] [Related]  

  • 8. High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China.
    Li H; Dong K; Fang Q; Hou X; Zhou M; Bao Y; Xiang K; Xu A; Jia W
    J Hepatol; 2013 Mar; 58(3):557-63. PubMed ID: 23142063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts.
    Papatheodoridi M; Cholongitas E
    Curr Pharm Des; 2018; 24(38):4574-4586. PubMed ID: 30652642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis.
    Traussnigg S; Kienbacher C; Gajdošík M; Valkovič L; Halilbasic E; Stift J; Rechling C; Hofer H; Steindl-Munda P; Ferenci P; Wrba F; Trattnig S; Krššák M; Trauner M
    Liver Int; 2017 Oct; 37(10):1544-1553. PubMed ID: 28544208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline HOMA IR and Circulating FGF21 Levels Predict NAFLD Improvement in Patients Undergoing a Low Carbohydrate Dietary Intervention for Weight Loss: A Prospective Observational Pilot Study.
    Watanabe M; Risi R; Camajani E; Contini S; Persichetti A; Tuccinardi D; Ernesti I; Mariani S; Lubrano C; Genco A; Spera G; Gnessi L; Basciani S
    Nutrients; 2020 Jul; 12(7):. PubMed ID: 32708435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic accuracy of serum alanine aminotransferase as biomarker for nonalcoholic fatty liver disease and insulin resistance in healthy subjects, using 3T MR spectroscopy.
    Martin-Rodriguez JL; Gonzalez-Cantero J; Gonzalez-Cantero A; Arrebola JP; Gonzalez-Calvin JL
    Medicine (Baltimore); 2017 Apr; 96(17):e6770. PubMed ID: 28445310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.
    Arora A; Sharma P
    J Clin Exp Hepatol; 2012 Jun; 2(2):145-55. PubMed ID: 25755423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease.
    Wasilewska N; Bobrus-Chociej A; Harasim-Symbor E; Tarasów E; Wojtkowska M; Chabowski A; Lebensztejn DM
    Lipids Health Dis; 2018 Sep; 17(1):216. PubMed ID: 30208901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Value of hydrogen proton magnetic resonance spectroscopy in the determination of liver triglyceride in patients with fatty liver disease and its influencing factors].
    Qu HJ; Wang L; Jin PH; Gao Q; Zhou JX; Song Y; Wang J; Jiang YM; Gong L; Chen GY; Ding JP; Shi JP
    Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):858-863. PubMed ID: 29325281
    [No Abstract]   [Full Text] [Related]  

  • 16. [Correlation between intrahepatic triglyceride content quantified by proton magnetic resonance spectroscopy and glucose metabolism].
    Long XX; Liu D; Wu L; Qian LL; Fang QC; Li HT; Jia WP
    Zhonghua Nei Ke Za Zhi; 2021 Dec; 60(12):1157-1164. PubMed ID: 34856688
    [No Abstract]   [Full Text] [Related]  

  • 17. Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease.
    Motamed N; Sohrabi M; Ajdarkosh H; Hemmasi G; Maadi M; Sayeedian FS; Pirzad R; Abedi K; Aghapour S; Fallahnezhad M; Zamani F
    World J Gastroenterol; 2016 Mar; 22(10):3023-30. PubMed ID: 26973398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrasound hepatic/renal ratio and hepatic attenuation rate for quantifying liver fat content.
    Zhang B; Ding F; Chen T; Xia LH; Qian J; Lv GY
    World J Gastroenterol; 2014 Dec; 20(47):17985-92. PubMed ID: 25548498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor 21 in non-alcoholic fatty liver disease.
    Tucker B; Li H; Long X; Rye KA; Ong KL
    Metabolism; 2019 Dec; 101():153994. PubMed ID: 31672443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers.
    Shen J; Chan HL; Wong GL; Choi PC; Chan AW; Chan HY; Chim AM; Yeung DK; Chan FK; Woo J; Yu J; Chu WC; Wong VW
    J Hepatol; 2012 Jun; 56(6):1363-70. PubMed ID: 22314419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.